Mian, Hira http://orcid.org/0000-0003-1584-1067
Kaiser, Martin http://orcid.org/0000-0002-3677-4804
Fonseca, Rafael http://orcid.org/0000-0002-5938-3769
Article History
Received: 13 November 2023
Revised: 29 December 2023
Accepted: 4 January 2024
First Online: 16 January 2024
Competing interests
: HM: Honoraria: BMS, Janssen, Abbvie, Pfizer, Forus, GSK, Sanofi, Amgen, Takeda; Research funding Janssen. MK: Honoraria: Janssen, Takeda, AbbVie, Sanofi; Consulting or advisory role: AbbVie, GSK, Janssen, Pfizer, Seattle Genetics, Takeda; Research funding: BMS/Celgene (to institution), Janssen (to institution). RF: Consulting: AbbVie, Adaptive Biotechnologies, AMGEN, AZeneca, Bayer, Binding Site, BMS (Celgene), Millenium Takeda, Jansen, Juno, Kite, Merck, Pfizer, Pharmacyclics, Regeneron, Sanofi; Scientific Advisory Boards: Adaptive Biotechnologies, Caris Life Sciences, Oncotracker.; Board of Directors<b>:</b> Antegene (for profit), AZBio (not for Profit); Patent for FISH in MM - ~$2000/year.